313 related articles for article (PubMed ID: 36966266)
1. Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes.
Wang C; Sallman DA
Curr Treat Options Oncol; 2023 May; 24(5):387-408. PubMed ID: 36966266
[TBL] [Abstract][Full Text] [Related]
2. New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A; Bravo GM
Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
[TBL] [Abstract][Full Text] [Related]
3. Novel therapies in low- and high-risk myelodysplastic syndrome.
Germing U; Schroeder T; Kaivers J; Kündgen A; Kobbe G; Gattermann N
Expert Rev Hematol; 2019 Oct; 12(10):893-908. PubMed ID: 31353975
[No Abstract] [Full Text] [Related]
4. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
5. Raising the bar for lower-risk myelodysplastic syndromes.
Venugopal S; Sekeres MA
Leuk Lymphoma; 2023 Jun; 64(6):1082-1091. PubMed ID: 37029589
[TBL] [Abstract][Full Text] [Related]
6. The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances.
Randall MP; DeZern AE
Cancer J; 2023 May-Jun 01; 29(3):152-159. PubMed ID: 37195771
[TBL] [Abstract][Full Text] [Related]
7. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2014 Jan; 89(1):97-108. PubMed ID: 24464505
[TBL] [Abstract][Full Text] [Related]
8. [Management of lower-risk myelodysplastic syndromes].
Ichikawa M
Rinsho Ketsueki; 2020; 61(9):1212-1217. PubMed ID: 33162518
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic approaches for the management of higher risk myelodysplastic syndromes.
Wang C; Sallman DA
Leuk Lymphoma; 2023 Mar; 64(3):511-524. PubMed ID: 36433645
[TBL] [Abstract][Full Text] [Related]
10. Myelodysplastic syndromes: moving towards personalized management.
Hellström-Lindberg E; Tobiasson M; Greenberg P
Haematologica; 2020 Jul; 105(7):1765-1779. PubMed ID: 32439724
[TBL] [Abstract][Full Text] [Related]
11. Myelodysplastic syndromes current treatment algorithm 2018.
Steensma DP
Blood Cancer J; 2018 May; 8(5):47. PubMed ID: 29795386
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Garcia-Manero G; Chien KS; Montalban-Bravo G
Am J Hematol; 2020 Nov; 95(11):1399-1420. PubMed ID: 32744763
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2023 Aug; 98(8):1307-1325. PubMed ID: 37288607
[TBL] [Abstract][Full Text] [Related]
14. Clinical decision-making and treatment of myelodysplastic syndromes.
Hellström-Lindberg ES; Kröger N
Blood; 2023 Dec; 142(26):2268-2281. PubMed ID: 37874917
[TBL] [Abstract][Full Text] [Related]
15. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2012 Jul; 87(7):692-701. PubMed ID: 22696212
[TBL] [Abstract][Full Text] [Related]
16. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant.
Bewersdorf JP; Stahl M; Zeidan AM
Expert Rev Hematol; 2019 Aug; 12(8):575-578. PubMed ID: 31225770
[TBL] [Abstract][Full Text] [Related]
17. Evolving therapies for lower-risk myelodysplastic syndromes.
Bewersdorf JP; Zeidan AM
Ann Hematol; 2020 Apr; 99(4):677-692. PubMed ID: 32078008
[TBL] [Abstract][Full Text] [Related]
18. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
Montalban-Bravo G; Garcia-Manero G
Am J Hematol; 2018 Jan; 93(1):129-147. PubMed ID: 29214694
[TBL] [Abstract][Full Text] [Related]
19. [Treatment for low-risk myelodysplastic syndromes].
Morita Y
Rinsho Ketsueki; 2018; 59(10):2050-2057. PubMed ID: 30305508
[TBL] [Abstract][Full Text] [Related]
20. Therapy for lower-risk MDS.
Carraway HE; Saygin C
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):426-433. PubMed ID: 33275714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]